

# Optimizing the Efficiency and Quality of Sipuleucel-T Delivery in an Academic Institution

Kristen Davis, MHS, PA-C, Sarah Wood, RN, MSN, ANP, AOCNP®, Emily Dill, RN, MSN, ANP-BC, Yuri Fesko, MD, Rhonda L. Bitting, MD, Michael R. Harrison, MD, Andrew J. Armstrong, MD, ScM, Judd W. Moul, MD, and Daniel J. George, MD



© Oncology Nursing Society

**Background:** Sipuleucel-T, an autologous cellular immunotherapy, is approved for the treatment of certain patients with metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-T is the first personalized treatment for prostate cancer to be manufactured using the immune system of each individual patient. Patient preparation and compliance are critical because patients undergo serial leukapheresis and reinfusion procedures within a relatively short time period, which may result in transient reactions.

**Objectives:** The study aims to identify patients best suited for sipuleucel-T treatment, provide an overview of treatment, and encourage infusion sites to consider a primary contact model for the efficient coordination of care.

**Methods:** Treatment experiences were evaluated from 124 patients with mCRPC who received sipuleucel-T from January 2010 to August 2013 according to current best practices. Feedback was collected from reflective interdisciplinary discussion within the sipuleucel-T delivery team (nurses, advanced practice providers, urologists, and medical oncologists).

**Findings:** Early patient identification and education on treatment rationale, delivery, and expectations help ensure a successful sipuleucel-T treatment experience. A multidisciplinary coordinated-care process can facilitate proficient sipuleucel-T delivery, and the selection of a primary contact for care coordination offers benefits, such as clear and efficient education.

Kristen Davis, MHS, PA-C, is a physician assistant and Sarah Wood, RN, MSN, ANP, AOCNP®, is a nurse practitioner, both in the Department of Medicine, Division of Medical Oncology, at Duke Cancer Institute in Durham, NC; Emily Dill, RN, MSN, ANP-BC, is a nurse practitioner at Duke Raleigh Hospital in Raleigh, NC; Yuri Fesko, MD, is an associate professor of medicine at Duke Raleigh Hospital and the Duke Cancer Institute; Rhonda L. Bitting, MD, is an assistant professor of Hematology and Oncology at Wake Forest Baptist Health in Winston-Salem, NC; and Michael R. Harrison, MD, is an assistant professor in the Department of Medicine, Division of Medical Oncology, Andrew J. Armstrong, MD, ScM, is an associate professor in the Department of Medicine, Division of Medical Oncology, and the Department of Surgery, Division of Urology, Judd W. Moul, MD, is the James H. Semans, MD, professor of surgery in the Department of Surgery, Division of Urology, and Daniel J. George, MD, is an associate professor in the Department of Medicine, Division of Medical Oncology, and the Department of Surgery, Division of Urology, all at Duke Cancer Institute. The authors take full responsibility for the content of the article. This study was funded, in part, by Dendreon Corporation. Davis, Harrison, Armstrong, Moul, and George have speakers' bureau affiliations with Dendreon Corporation. Davis and Harrison also have held advisory board positions with Dendreon Corporation, and Armstrong, Moul, and George have had consultant roles. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers or editorial staff. Davis can be reached at kristen.tracey@duke.edu, with copy to editor at CJONEditor@ons.org. (Submitted March 2014. Revision submitted September 2014. Accepted for publication September 22, 2014.)

Key words: sipuleucel-T; immunotherapy; castration-resistant prostate cancer; metastatic; best practice

Digital Object Identifier: 10.1188/15.CJON.297-303

Sipuleucel-T is an autologous cellular immunotherapy approved by the U.S. Food and Drug Administration (FDA) in April 2010 for the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant (previously termed “hormone-refractory”) prostate cancer (mCRPC) (Dendreon Corporation, 2010). Sipuleucel-T is unique in its field as the first personalized treatment for prostate cancer manufactured using the immune system of each individual patient (Drake, 2010).

Research on sipuleucel-T has demonstrated statistically significant improvement in overall survival in men with asymp-

tomatic to minimally symptomatic mCRPC being treated with sipuleucel-T. In the phase III Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) trial, sipuleucel-T improved median survival by 4.1 months (25.8 months with sipuleucel-T versus 21.7 months with placebo), improved three-year survival by 38%, and reduced the relative risk of death by 22% compared with placebo ( $p = 0.03$ ) (Kantoff et al., 2010) (see Figure 1).

An integrated analysis of two earlier phase III trials also indicated that sipuleucel-T was associated with a significant survival benefit (Higano et al., 2009; Small et al., 2006). However, neither study demonstrated a difference between sipuleucel-T and